Over the years, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has upheld the success of developing a pipeline of a wide range of treatments. Its primary target is the endocannabinoid system. CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist is one of the treatments included in the company’s pipeline among others.
However, CRBP is presenting three abstracts showing the positive correlation between the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (ACR CRISS) score and significant progress various patient-reported outcomes.
The presentation at the 6th Systemic Sclerosis World E-Congress further expounds on how the ACR CRISS score generally impacts the baseline of the patients’ feelings and functioning. There will be both oral recorded and poster presentations. Later, Professor Christopher Denton, Head of Centre and Consultant Rheumatologist, University College London Division of Medicine, will host a satellite symposium titled “The Role of the Endocannabinoid System in Chronic Inflammation and Fibrosis.”
Systemic sclerosis is a rare disease, but its impacts are huge
Systemic sclerosis is primarily chronic and a very rare disorder characterized by swelling and discoloration of the fingers, freezing joints. Severe damages can occur to the gastrointestinal system, including the heart, kidneys, and lungs.
Sadly, research indicates that even though organ dysfunction can be treated, there is no known cure for systemic sclerosis, which is more common among women aged 20 to 50. Close to 200,000 people in the EU, Japan, and North America suffer from the debilitating autoimmune disease.
What is the future of Corbus Pharmaceuticals?
The company seems to be pioneering in the transformation of the pharmaceutical industry. Its commitment and determination are fixated towards the completion of various studies expected to offer improved novel therapeutics for inflammatory and fibrotic diseases.
The company is hopeful that one of the treatments, Lenabasum, currently under evaluation in systemic sclerosis and cystic fibrosis, will be endorsed. Cystic fibrosis is also alleged to be a genetic but rare disease affecting more than 70,000 people worldwide.
Nonetheless, clinical studies to date indicate that Lenabasum presents acceptable safety and tolerability profiles.